StockData
Braveheart Bio, Inc. logo

Braveheart Bio, Inc. (BRVE) stock

BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.78−0.71 (-3.64%)

Close on Nov 17, 2026Market cap $1.69BP/E –Yield –

Braveheart Bio r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$17.54M–
Q2 FY2026Jun 30, 2026$11.13M–
Q3 FY2025Sep 30, 2025$9.00K–
Q2 FY2025Jun 30, 2025$0–

More Braveheart Bio figures

See a number that looks wrong?